Meilleurs médecins d'anémie aplastique à l'étranger — Page 3

A réalisé plus de 3 500 greffes de moelle osseuse – reconnu par Forbes comme l'un des meilleurs médecins en 2018.

• _doctor_3609_années_ d'expérience en hématologie pédiatrique
• Spécialisé dans le traitement des enfants atteints de maladies du sang rares
• Connu parmi les patients comme 'celui qui transplante la vie'
• Travaille au centre médical Hadassah

Le Dr Hila Magen est une hématologue-oncologue israélienne de premier plan au centre médical Sheba. Elle dirige l'unité de myélome multiple et d'amylose. Le Dr Magen est spécialisée dans le traitement des troubles complexes des plasmocytes et du myélome à haut risque. Elle est chercheuse principale pour des programmes innovants de thérapie CAR-T au point de service. Ses travaux intègrent des immunothérapies avancées dans les soins cliniques de routine.

• Auteure de plus de 100 publications scientifiques et d'études marquantes sur le myélome.
• A effectué des fellowships au MD Anderson et à l'Université des sciences médicales de l'Arkansas.
• Réalise des thérapies par cellules CAR-T et des greffes de moelle osseuse.
• Travaille au centre médical Sheba, classé 7e mondial en 2026 par Newsweek.

Le Dr Avichai Shimoni est directeur de la transplantation de moelle osseuse au Sheba Medical Center. Il traite des cancers du sang complexes. Il a effectué un fellowship spécialisé au MD Anderson Cancer Center. Le Dr Shimoni utilise des greffes allogéniques et autologues pour les patients à haut risque. Il est professeur et président d'hématologie à l'Université de Tel Aviv.

• Nommé parmi les meilleurs médecins d'Israël par Forbes pour 2025 et 2026.
• Auteur de plus de 250 articles scientifiques sur les thérapies cellulaires et la transplantation.
• Propose une thérapie par cellules CAR-T pour la leucémie, le lymphome et le myélome multiple.
• Travaille au Sheba Medical Center, l'un des 10 meilleurs hôpitaux au monde selon Newsweek.

Le Dr Spielberg est un onco-hématologue dévoué au centre médical Assuta, spécialisé dans les troubles sanguins tels que l'anémie aplasique.

• Il se concentre à la fois sur le diagnostic et sur la planification complète du traitement
• Expert dans la gestion des syndromes d'insuffisance médullaire
• Travaille dans le plus grand hôpital privé d'Israël, le centre médical Assuta
• Fournit des soins personnalisés pour les affections hématologiques complexes

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Le Dr Abraham Avigdor est directeur de l'Institut d'hématologie du centre médical Sheba. Il est une autorité mondiale en matière de lymphome, de thérapie CAR-T et de cancers du sang complexes. Le Dr Avigdor a fondé le groupe de travail israélien sur les lymphomes. Il participe à la direction d'une clinique classée 7e au niveau mondial par Newsweek en 2026.

• Auteur de plus de 130 publications scientifiques sur l'hémato-oncologie et la thérapie cellulaire.
• Pionnier de l'intégration de la thérapie par cellules CAR-T pour le lymphome et le myélome.
• Dirige des programmes de greffe de moelle osseuse allogénique et autologue.
• A été président du groupe d'étude israélien sur les lymphomes.

La Prof. Elke Jaeger est chef du service d'oncologie et d'hématologie à Nordwest – une spécialiste de premier plan des sarcomes, reconnue par le classement Focus.

• _doctor_502_ans_ de pratique spécialisée en oncologie et hématologie
• Reconnue comme l'une des meilleures oncologues d'Allemagne
• Expertise particulière dans le traitement des maladies rares du sang

Le professeur associé Rafet Eren est spécialisé en hématologie et compte plus de 50 publications dans des revues internationales, reflétant une expertise approfondie des troubles sanguins.

• Doctorat en hématologie obtenu à l'hôpital de formation et de recherche d'Istanbul
• Membre de la Société européenne d'hématologie
• Lauréat du prix du jeune chercheur en 2016
• Maîtrise de l'anglais pour les consultations internationales

Le Prof. Kaynar dirige le département d'hématologie et de greffe de moelle osseuse à l'hôpital universitaire Medipol Mega, avec une vaste expérience dans les greffes de moelle osseuse et l'anémie aplasique.

• Ancien chef du service d'hématologie à l'université d'Erciyes
• A dirigé l'unité d'aphérèse pendant 16 années
• Chercheur invité au centre de greffe de moelle osseuse de l'université Duke
• Spécialisé en hématologie bénigne et maligne

Le Dr Apak est spécialisé en hématologie-oncologie pédiatrique avec _doctor_6792_ années_ d'expérience, se concentrant sur la greffe de moelle osseuse et la thérapie par cellules CAR-T à l'hôpital universitaire Biruni.

• Chef de la division d'hématologie-oncologie pédiatrique à l'Université d'Istanbul-Cerrahpaşa
• Auteur de 75 publications internationales en oncologie pédiatrique
• Rédacteur adjoint du périodique Turkish Pediatrics Archives
• Membre du conseil d'administration de la Société turque de pédiatrie

Le Pr Fabio Ciceri dirige l'unité d'hématologie et de transplantation de moelle osseuse de l'hôpital de recherche San Raffaele, un centre spécialisé dans les thérapies avancées pour les troubles sanguins.

• Investigateur principal dans des essais cliniques sur les cancers hématologiques et les déficits immunitaires
• Auteur de plus de 180 articles de recherche en hématologie et transplantation
• Membre de nombreuses sociétés prestigieuses, dont le Groupe européen de transplantation de sang et de moelle osseuse

Le Prof. Dr. Serdar Bedii Omay a publié plus de 65 articles scientifiques sur l'hématologie, axés sur les traitements avancés à l'hôpital Emsey.

• Spécialisé en hématologie et en greffe de moelle osseuse
• Formé en hématologie moléculaire à l'école de médecine de Mie, au Japon
• Professeur d'hématologie avec des décennies d'expérience académique
• A présenté lors de 34 conférences internationales

Le Prof. Baytan est spécialisé en hématologie et oncologie pédiatrique, avec un accent sur les cancers de l'enfant et les greffes de moelle osseuse à l'hôpital Emsey.

• 15 articles publiés dans des revues internationales à comité de lecture
• Expert dans les traitements de l'anémie et des carences en fer
• Professeur à l'Université d'Uludağ avec de nombreuses fonctions académiques
• Spécialisé dans les greffes de moelle osseuse pédiatriques

Le Dr Eckhart Weidmann dirige le secteur d'hématologie à la clinique Nordwest, spécialisé dans le traitement des troubles sanguins avec plus de _doctor_501_années_ de pratique.

• Expert en lymphome non hodgkinien et en anémie aplasique
• Professeur possédant une vaste expérience académique et clinique
• Dirige une équipe dédiée aux traitements des troubles sanguins

Le professeur associé Ali Hakan Kaya est spécialisé en hématologie et en greffe de cellules souches, avec une formation approfondie dans les meilleurs hôpitaux turcs.

• Sous-spécialiste en hématologie avec un accent sur la greffe de cellules souches
• Chercheur primé à plusieurs reprises en oncologie hématologique
• Membre de la Société turque d'aphérèse et de la Société d'immunologie hématologique
• Travaille au sein du département d'hématologie avancée de l'hôpital universitaire Biruni

Chef du centre de transplantation de moelle osseuse de l'hôpital universitaire d'Essen – spécialisé en onco-hématologie.

• Dirige l'un des meilleurs centres de transplantation d'Allemagne
• Expert en procédures de transplantation de moelle osseuse
• Se concentre sur les tumeurs malignes et les troubles hématologiques

Le Dr Kalashetty est spécialisé dans la greffe de moelle osseuse pour l'anémie aplasique aux hôpitaux Manipal.

• Onco-hématologue expert en troubles sanguins
• Se concentre sur les procédures de greffe de moelle osseuse
• Travaille dans l'un des principaux établissements de santé en Inde